NovoCure (NVCR) Net Margin (2014 - 2026)
NovoCure (NVCR) posted quarterly Net Margin of 8.53% for Q2 2026, up 1675.0% year-on-year from 0.48% in Q2 2025, and up 79.13% on a QoQ basis from 40.87% in Q1 2026.
NovoCure (NVCR) Net Margin (2014 - 2026) Analysis & Trends
NovoCure (NVCR) has reported Net Margin for 13 consecutive years, with 8.53% the latest figure, recorded in Q2 2026.
- Quarterly Net Margin rose 1675.0% year-over-year to 8.53% in Q2 2026, while the trailing twelve-month figure through Jun 2026 was 21.25% (up 588.0% YoY) and the FY2025 annual result came in at 20.79%, up 708.0% from the prior year.
- Net Margin improved to 8.53% in Q2 2026 per NVCR's latest filing, from 40.87% in the prior quarter.
- Over the last five years, Net Margin for NVCR reached as high as 3.38% in Q1 2022 and fell as low as 45.55% in Q2 2023.
- A 5-year average of 26.48% and a median of 23.78% in 2025 frame the typical range for Net Margin.
- Annual changes were most pronounced in 2023 — Net Margin sank 4005 bps — and 2025, when it jumped 2683 bps.
- Year by year, Net Margin stood at 29.05% in 2022, then declined by 21 bps to 35.19% in 2023, then fell by 16 bps to 40.88% in 2024, then jumped by 66 bps to 14.05% in 2025, then surged by 39 bps to 8.53% in 2026.
- According to Business Quant data, Net Margin over the past three periods registered 8.53%, 40.87%, and 14.05% for Q2 2026, Q1 2026, and Q4 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 201.40 Bn | 194.75 Bn | 6.27 Bn | 9.65% |
| 2 | Stryker | 122.29 Bn | 119.41 Bn | 3.81 Bn | 12.38% |
| 3 | Medtronic | 105.01 Bn | 96.40 Bn | 6.41 Bn | 12.84% |
| 4 | Boston Scientific | 64.81 Bn | 63.59 Bn | 3.61 Bn | 25.77% |
| 5 | Edwards Lifesciences | 55.28 Bn | 51.60 Bn | 1.29 Bn | - |
| 6 | Dexcom | 29.06 Bn | 27.94 Bn | 750.30 Mn | 16.74% |
| 7 | Koninklijke Philips | 29.02 Bn | 25.93 Bn | 2.07 Bn | 3.87% |
| 8 | GE HealthCare Technologies | 28.27 Bn | 26.20 Bn | 1.98 Bn | 8.01% |
| 9 | Smith & Nephew | 25.80 Bn | 25.22 Bn | - | - |
| 10 | NovoCure | 2.28 Bn | 1.85 Bn | 142.48 Mn | -8.53% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -8.53% |
| Mar 31, 2026 | -40.87% |
| Dec 31, 2025 | -14.05% |
| Sep 30, 2025 | -22.29% |
| Jun 30, 2025 | -25.28% |
| Mar 31, 2025 | -22.14% |
| Dec 31, 2024 | -40.88% |
| Sep 30, 2024 | -19.71% |
| Jun 30, 2024 | -22.20% |
| Mar 31, 2024 | -27.98% |
| Dec 31, 2023 | -35.19% |
| Sep 30, 2023 | -38.87% |
| Jun 30, 2023 | -45.55% |
| Mar 31, 2023 | -43.43% |
| Dec 31, 2022 | -29.05% |
| Sep 30, 2022 | -20.29% |
| Jun 30, 2022 | -17.04% |
| Mar 31, 2022 | -3.38% |
| Dec 31, 2021 | -19.86% |
| Sep 30, 2021 | -9.82% |